AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021
Breast Care (Source: Breast Care)
Source: Breast Care - June 1, 2021 Category: Cancer & Oncology Source Type: research
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
Breast Care (Source: Breast Care)
Source: Breast Care - May 27, 2021 Category: Cancer & Oncology Source Type: research
Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy
Conclusion: The real-world beneficial effects of NEPA prophylaxis on QoL were confirmed for patients with breast cancer receiving AC. NEPA was effective with a good safety profile in this patient population in clinical practice.Breast Care (Source: Breast Care)
Source: Breast Care - May 25, 2021 Category: Cancer & Oncology Source Type: research
Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)
Conclusions: Our results do not confirm previous findings that greater body height is associated with a higher breast cancer risk and worse outcome.Breast Care (Source: Breast Care)
Source: Breast Care - May 21, 2021 Category: Cancer & Oncology Source Type: research
Treatment Strategy for Patients with HR-Positive HER2-Negative Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors
Conclusion: Our study shows that mTOR inhibitors might be an effective treatment option for patients with HR+ HER2 − MBC previously treated with CDK4/6 inhibitors.Breast Care (Source: Breast Care)
Source: Breast Care - May 21, 2021 Category: Cancer & Oncology Source Type: research
Quality and Quantity: How to Organize a Countrywide Genetic Counseling and Testing
This article describes how to implement a concept of evidence-generating care for risk-adjusted prevention in a nationwide health care system.Breast Care (Source: Breast Care)
Source: Breast Care - May 7, 2021 Category: Cancer & Oncology Source Type: research
PharmaNews
Breast Care 2021;16:192 –192 (Source: Breast Care)
Source: Breast Care - April 19, 2021 Category: Cancer & Oncology Source Type: research
St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer
Because of the COVID-19 pandemic, the 2021 St. Gallen/Vienna Consensus Conference on Early Breast Cancer Treatment Standards had to be held virtually. Despite the challenge of convening global contributors to both the conference itself as well as the important Consensus Panel, the scientific committee and the organizers managed to organize a well-received scientific conference, and also the panel discussion was well received in the worldwide scientific community, as indicated by numerous positive feedbacks already within the first 24 h. The virtual format was unusual, but opened the door for new elements such as Consensus ...
Source: Breast Care - April 7, 2021 Category: Cancer & Oncology Source Type: research
Long-Term Results of the TARGIT-A Trial: More Questions than Answers
Background: During the last decade, partial breast irradiation (PBI) has gained traction as a relevant treatment option for patients with early-stage low-risk breast cancer after breast-conserving surgery. The TARGIT-A prospective randomized trial compared a “risk-adapted” intraoperative radiotherapy (IORT) approach with 50-kv X-rays (INTRABEAM®) as the PBI followed by optional whole-breast irradiation (WBI) and conventional adjuvant WBI in terms of observed 5-year in-breast recurrence rates. Recently, long-term data were published. Since the first publication of the TARGIT-A trial, a broad debate has been emerged reg...
Source: Breast Care - April 6, 2021 Category: Cancer & Oncology Source Type: research
From < b > < i > BRCA1 < /i > < /b > to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes
Background: There has been huge progress over the last 30 years in identifying the familial component of breast cancer.Summary: Currently around 20% is explained by the high-risk genesBRCA1 andBRCA2, a further 2% by other high-penetrance genes, and around 5% by the moderate risk genesATM and CHEK2. In contrast, the more than 300 low-penetrance single-nucleotide polymorphisms (SNP) now account for around 28% and they are predicted to account for most of the remaining 45% yet to be found. Even for high-risk genes which confer a 40 –90% risk of breast cancer, these SNP can substantially affect the level of breast cancer ris...
Source: Breast Care - March 31, 2021 Category: Cancer & Oncology Source Type: research
When Is Sentinel Node Biopsy Indicated in High-Risk Ductal Carcinoma in situ? Four Hundred Sixty-Eight Cases from Three Institutions
Conclusions: The results suggest that high-grade DCIS or DCIS with a size #x3e;3 cm, independently, does not require SLNB. Nonetheless, in the event that both factors are found in the same case, SLNB may be indicated. Additionally, SLNB is advisable for DCIS cases that are palpable or show a mass effect on mammography.Breast Care (Source: Breast Care)
Source: Breast Care - March 30, 2021 Category: Cancer & Oncology Source Type: research
Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer – Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT)
Conclusion: We showed that the results of the MINDACT trial are reproducible in an Austrian population. Incorporating 70-GS into the daily clinical routine is feasible and mostly accepted by physicians for the guidance of treatment recommendations.Breast Care (Source: Breast Care)
Source: Breast Care - March 30, 2021 Category: Cancer & Oncology Source Type: research
Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review
Conclusion: The reported clinical trials highlight that checkpoint inhibition seems to be promising in metastatic, neoadjuvant, and adjuvant settings of HER2-positive breast cancer.Breast Care (Source: Breast Care)
Source: Breast Care - March 29, 2021 Category: Cancer & Oncology Source Type: research
Expert Discussion: Immunotherapy in Breast Cancer – Ready for Prime Time?
Breast Care (Source: Breast Care)
Source: Breast Care - March 26, 2021 Category: Cancer & Oncology Source Type: research
Fifteen Years of < b > < i > Breast Care < i > < b >
Breast Care (Source: Breast Care)
Source: Breast Care - March 26, 2021 Category: Cancer & Oncology Source Type: research
